Table 2 Comparison of Persons Who Switched Treatments

Characteristic	Non-switchers, N = 182^a	Switchers, N = 195^a	p-value^b
Sex			0.007
Woman	110 (60%)	91 (47%)
Man	72 (40%)	104 (53%)
Age (years)	63 (54, 69)	60 (54, 67)	0.077
Familial hypercholesterolemia			>0.9
Familial hypercholesterolemia	109 (60%)	118 (61%)
Non-Familial hypercholesterolemia	73 (40%)	77 (39%)
Lipid modifying drugs
Any statins	74 (41%)	113 (58%)	<0.001
High dose statins	30 (16%)	50 (26%)	0.030
Moderate dose statins	29 (16%)	29 (15%)	0.8
Low dose statins	15 (8.2%)	34 (17%)	0.008
Fibrates	23 (13%)	26 (13%)	0.8
Bile acid sequestrants	7 (3.8%)	9 (4.6%)	0.7
Ezetimibe	118 (65%)	137 (70%)	0.3
Number of lipid modifying drugs			0.004
0 drugs	39 (21%)	19 (9.7%)
1 drug	73 (40%)	78 (40%)
2+ drugs	70 (38%)	98 (50%)
Comorbidities
Atherosclerotic cardiovascular disease	115 (63%)	132 (68%)	0.4
Coronary heart disease	102 (56%)	112 (57%)	0.8
Atherosclerotic cerebrovascular disease	20 (11%)	20 (10%)	0.8
Peripheral artery disease	18 (9.9%)	18 (9.2%)	0.8
Hypertension	119 (65%)	115 (59%)	0.2
Diabetes mellitus	41 (23%)	30 (15%)	0.076
Diabetes mellitus with organ damage	22 (12%)	22 (11%)	0.8
Heart failure	18 (9.9%)	16 (8.2%)	0.6
Chronic obstructive pulmonary disease	23 (13%)	17 (8.7%)	0.2
Rheumatoid arthritis	9 (4.9%)	5 (2.6%)	0.2
Cancer, ex. non-melanoma skin cancer	12 (6.6%)	15 (7.7%)	0.7
Chronic kidney disease	5 (2.7%)	3 (1.5%)	0.5
Allergies
Number of allergies			0.13
0	79 (43%)	107 (55%)
1	40 (22%)	35 (18%)
01-mar	44 (24%)	33 (17%)
4+	19 (10%)	20 (10%)
Statin allergy	58 (32%)	57 (29%)	0.6
Ezetimibe allergy	16 (8.8%)	18 (9.2%)	0.9

^an (%); Median (IQR)
^bPearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test
This table compares the demographic and clinical characteristics of persons who switched treatments during the first year of the study to those who did not switch. Variables such as age, gender, baseline lipid measurements, and comorbidities are included. Chi-squared and Wilcoxon rank sum tests were used to compare the group of persons who switched to evolocumab with the group who did not switch. Atherosclerotic cardiovascular disease in this context includes all ICD-10 codes corresponding to coronary heart disease, cerebrovascular disease, and peripheral artery disease. Statins were classified as follows: Simvastatin (low: 0 mg, moderate: 20 mg, high: 80 mg), Pravastatin (low: 0 mg, moderate: 40 mg), Fluvastatin (low: 0 mg, moderate: 80 mg), Atorvastatin (low: 0 mg, moderate: 10 mg, high: 40 mg), and Rosuvastatin (low: 0 mg, moderate: 5 mg, high: 20 mg).

Search